| Literature DB >> 27074476 |
Victy Y W Wong1, Colin R Baker, T W Leung, Stewart Y Tung.
Abstract
The study was aimed to introduce a design of a DICOM-RT-based tool box to facilitate 4D dose calculation based on deformable voxel-dose registration. The computational structure and the calculation algorithm of the tool box were explicitly discussed in the study. The tool box was written in MATLAB in conjunction with CERR. It consists of five main functions which allow a) importation of DICOM-RT-based 3D dose plan, b) deformable image registration, c) tracking voxel doses along breathing cycle, d) presentation of temporal dose distribution at different time phase, and e) derivation of 4D dose. The efficacy of using the tool box for clinical application had been verified with nine clinical cases on retrospective-study basis. The logistic and the robustness of the tool box were tested with 27 applications and the results were shown successful with no computational errors encountered. In the study, the accumulated dose coverage as a function of planning CT taken at end-inhale, end-exhale, and mean tumor position were assessed. The results indicated that the majority of the cases (67%) achieved maximum target coverage, while the planning CT was taken at the temporal mean tumor position and 56% at the end-exhale position. The comparable results to the literature imply that the studied tool box can be reliable for 4D dose calculation. The authors suggest that, with proper application, 4D dose calculation using deformable registration can provide better dose evaluation for treatment with moving target.Entities:
Mesh:
Year: 2016 PMID: 27074476 PMCID: PMC5875557 DOI: 10.1120/jacmp.v17i2.5935
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1DE‐DOSE‐REG function: (a) description of 3D array dose point in CERR; (b) the morphing process (M denotes the deformation matrix); (c) combination of the 3D dose array and M matrix for 4D dose calculation.
Figure 2An example of 4D dose calculation: (a) dose distribution shown at end‐inhale phase with the planning CT taken at the end‐exhale phase; (b) target doses received at different phases and the corresponding DVHs; (c) accumulated target dose for a complete respiratory cycle; (d) the DVH of the accumulated target dose.
Figure 3denotes dose received at the x% breathing phase by multiplying a time weighting factor to .
Figure 4A flowchart of the 4D tool box.
The disease characteristics
|
|
|
|
|
|
|---|---|---|---|---|
| 1 |
| LUL | 3.4% | 5.8 (LAT) 1.6 (AP) 0.3 (CC) 6.0 (RES) |
| 2 |
| LUL | 9.5% | 0.5 (LAT) 2.6 (AP) 3.5 (CC) 4.4 (RES) |
| 3 |
| RLL | 9.8% | 0.5 (LAT) 2.6 (AP) 3.0 (CC) 4.0 (RES) |
| 4 |
| LUL | 8.5% | 1.1 (LAT) 0.5 (AP) 0 (CC) 1.2 (RES) |
| 5 |
| RUL | 6.4% | 1.1 (LAT) 3.2 (AP) 3.0 (CC) 4.5 (RES) |
| 6 |
| RLL | 9.7% | 2.1(LAT) 1.6 (AP) 6.0 (CC) 6.6 (RES) |
| 7 |
| LUL | 3.3% | 1.5(LAT) 3.5 (AP) 0 (CC) 3.8 (RES) |
| 8 |
| LUL | unknown | 1.5 (LAT) 1.5 (AP) 9.0 (CC) 9.2 (RES) |
| 9 |
| LLL | unknown | 2.4(LAT) 8.3 (AP) 9.2 (CC) 10.5 (RES) |
; ; ; ; ; ; ; .
Matching indices between the manual_contour and the morph_contour of lung volume and of the GTV for all cases
|
| ||
|---|---|---|
|
|
| |
| 1 | 0.79 | 0.95 |
| 2 | 0.81 | 0.98 |
| 3 | 0.74 | 0.96 |
| 4 | 0.94 | 0.93 |
| 5 | 0.75 | 0.95 |
| 6 | 0.94 | 0.93 |
| 7 | 0.90 | 0.95 |
| 8 | 0.84 | 0.96 |
| 9 | 0.98 | 0.96 |
|
|
|
|
The mean conformity index (CI), the mean homogeneity index (HI), and the mean target coverage index (TGI) of the three phased‐specific dose plans. CI was evaluated at 99.5% target coverage. The amount of dose coverage as a function of planning CT taken at end‐exhale, end‐inhale, and mean tumor position is shown in the 5th to 7th columns
|
| ||||||
|---|---|---|---|---|---|---|
| Patient |
|
|
|
|
|
|
| 1 |
|
|
| 57.4b | 63.1 | 71.5 |
| 2 |
|
|
| 85.2 | 91.0 | 95.9 |
| 3 |
|
|
| 80.0 | 73.0 | 89.2 |
| 4 |
|
|
| 97.7 | 96.6 | 97.7 |
| 5 |
|
|
| 94.6 | 92.8 | 92.9 |
| 6 |
|
|
| 96.7 | 90.7 | 96.7 |
| 7 |
|
|
| 99.1 | 95.7 | 95.6 |
| 8 |
|
|
| 60.4 | 83.2 | 79.5 |
| 9 |
|
|
| 90.4 | 66.9 | 84.0 |
Indicates the maximum target dose coverage.
Indicates minimum coverage.